161Tb-DOTA-LM3

N/A

Report date: 2025/11/20 16:00:42

Base Information

Drug Name161Tb-DOTA-LM3

Drug Alias Name161Tb-DOTA-LM3

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Terbium > 161TbRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSomatostatin receptor 2 antagonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Hospital Basel

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Basel

Inactive CompaniesN/A

Active IndicationsGastroenteropancreatic neuroendocrine tumorNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A